2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…2016 American Transplant Congress
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.
Antibody mediated lymphocyte depletion is commonly used in clinical transplantation. However, memory T cells undermine the efficacy of lymphoablative induction therapies in sensitized transplant recipients.…2015 American Transplant Congress
Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.
Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…2015 American Transplant Congress
Effect of Induction in Renal Transplant Recipients Aged 70 and Over
Transplantation, Montefiore Medical Center, Bronx, NY.
While there is a significant survival advantage to transplanting patients 70 years of age and older versus staying on dialysis, it is unclear whether sensitized…2015 American Transplant Congress
Kidney Patients at High Immunological Risk Can Be Safely Transplanted With a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab
Purpose: We report the outcomes from our single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative…2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
1The University of Toledo Medical Center, Toledo, OH; 2The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…2015 American Transplant Congress
Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
1Transplant, Mayo Clinic, Jacksonville, FL; 2Pharmacy, Mayo Clinic, Jacksonville, FL.
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients…2015 American Transplant Congress
Effectiveness of Protocol-Driven Induction Therapy in Adult Kidney Transplant Recipients
Background: Induction therapy significantly improves graft outcomes in kidney transplantation, but the optimal agent based on patient characteristics and immunologic risk is unknown. While many…2015 American Transplant Congress
Single Center Experience With the Use of an Abbreviated Anti-Thymocyte Globulin and Basiliximab Combination Protocol in Renal Transplantation
Purpose: To report one year outcomes from single center experience with a novel induction regimen using anti-thymocyte globulin ( ATG)(rabbit)rATG (3 mg/kg) in divided doses…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 31
- Next Page »